Tous Actualités
Suivre
Abonner Amersham Biosciences

Amersham Biosciences

Amersham Biosciences Updates CodeLink Informatics Solution to Provide Complete Data Management

Piscataway, NJ (ots)

Amersham Biosciences, the life
sciences business of Amersham (LSE:, NYSE:, OSE: AHM), has enhanced
its CodeLink™ Informatics Solution to help scientists to improve
productivity further by streamlining data extraction, acquisition and
management processes in their gene expression experiments.  The suite
of tools includes CodeLink Expression Analysis software, new
workflows added to the Scierra™ Microarray Laboratory Workflow
System (LWS) and compatibility with Scierra LWS DiscoveryHub™
platform.
Combined in the CodeLink Informatics Solution, is a powerful data
management tool for the CodeLink Gene Expression System enabling
researchers to produce, capture and integrate experimental data. The
CodeLink Expression Analysis Software has been developed as an
automated application for acquiring gene expression values from
CodeLink Bioarray images allowing users to process images from
multiple CodeLink validated scanners.  It also provides data output
compatible with commonly used downstream data analysis applications
including Rosetta Resolver™ and Luminator™, GeneSpring™,
SpotFire™, GeneSight™ and dChip.
The updated Scierra Microarray LWS offers complete data management
for the CodeLink bioarray workflow.  It has additional data
management capabilities and is compatible with one-color and
two-color pre-arrayed slide products, as well as multiple brands of
scanners and third party analysis software.  Scierra Microarray LWS
tracks the progress of samples through target preparation,
hybridisation, slide processing, image acquisition and expression
analysis. This open system is also MIAME/MAGE and FDA Regulation 21
CFR Part 11 compliant.
With the addition of Scierra LWS DiscoveryHub, scientists will be
able to quickly integrate their data generated by CodeLink and
Scierra Microarray LWS with any third party data, public data,
in-house data, clinical data, algorithms and applications.
"This total informatics solution for CodeLink experiments will
mean scientists carrying out gene expression experiments have access
to produce, capture and integrate data quickly and easily," comments
John Schneider, Vice President of Informatics Marketing at Amersham
Biosciences.  "With the ability to streamline the data extraction,
acquisition and management processes using the CodeLink Informatics
Solution, researchers will be able to dramatically increase the
efficiency of their basic drug discovery and research programmes."
Amersham Biosciences, the life sciences business of Amersham (LSE:
NYSE: OSE: AHM), is a world leader in developing and providing
integrated systems and solutions for disease research, drug
development and manufacture. Our systems are used to uncover the
function of genes and proteins, for the discovery and development of
drugs and for the manufacture of biopharmaceuticals. The
customers for Amersham Biosciences' products and technology are
pharmaceutical and biotechnology companies and research and academic
institutions, principally in North America, Europe, Latin America and
Asia. More information about Amersham Biosciences is available at
www.amershambiosciences.com
Amersham Biosciences-enabling molecular medicine
This information is provided by RNS
       The company news service from the London Stock Exchange
ots Original Text Service: Amersham Biosciences
Internet: http://www.presseportal.ch
Press contact:
Amersham Biosciences press contact:    
Helen Petts                            
PR Manager                             
+44 1494 498 068  
helen.petts@amersham.com
North America press contact:
Eric Rayvid
Evins Communications
+1 212 688 8200 
eric.rayvid@evins.com